Esmail Al-Ezzi

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Abhenil Mittal

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Zachary W Veitch

Division of Medical Oncology and Hematology, Royal Victoria Hospital, Barrie, ON, Canada

Amer Zahralliyali

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Nely Mercy Diaz Mejia

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Osama Abdeljalil

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Husam Alqaisi

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Vikaash Kumar

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Aaron R Hansen

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Cancer Services, Princess Alexandra Hospital, Metro South Health, Brisbane, QLD 4113, Australia

Nazanin Fallah-rad

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Srikala S Sridhar

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Keywords

immunotherapy, Kidney cancer, Non-Clear Cell Renal Cell Carcinoma, survival, targeted therapy

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi. org/10.3322/caac.21660
2. Brenner DR, Poirier A, Woods RR, Ellison LF, Billette JM, Demers AA, et al. Projected estimates of cancer in Canada in 2022. CMAJ. 2022;194(17):E601–7. https://doi.org/10.1503/ cmaj.212097
3. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs–part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. https://doi. org/10.1016/j.eururo.2016.02.029
4. Dong J, Xu W, Ji Z, Pan B. Xp11.2 translocation renal cell carcinoma: Clinical characteristics and potential prognostic predictors. Dis Markers. 2021;2021:5647933. https://doi. org/10.1155/2021/5647933
5. Nguyen DP, Vertosick EA, Corradi RB, Vilaseca A, Benfante NE, Touijer KA, et al. Histological subtype of renal cell carcinoma significantly affects survival in the era of par-tial nephrectomy. Urol Oncol. 2016;34(6):259.e1–8. https://doi. org/10.1016/j.urolonc.2016.01.005
6. Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open. 2021;4(1):e2021869. https://doi.org/10.1001/ jamanetworkopen.2020.21869
7. Heng DY, Choueiri TK. Nonclear cell renal cancer: Features and medical management. J Natl Compr Cancer Netw. 2009;7(6):659–65. https://doi.org/10.6004/jnccn.2009.0046
8. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20(9):2376–81. https://doi.org/10.1200/JCO.2002.11.123
9. Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A mul-ticentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–88. https://doi.org/10.1016/S1470-2045(15)00515-X
10. Pal SK, Tangen C, Thompson IM, Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. https://doi.org/10.1016/S0140-6736(21)00152-5
11. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab ver-sus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. https://doi.org/10.1056/NEJMoa1712126
12. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. https://doi.org/10.1056/NEJMoa1816714
13. Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekseev BY, et al. Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 2022;8(2):275– 80. https://doi.org/10.1001/jamaoncol.2021.5981
14. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell  MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15. https://doi.org/10.1056/NEJMoa1816047
15. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–41. https://doi.org/10.1056/NEJMoa2026982
16. Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic therapies for the management of non-clear cell renal cell carcinoma: What works, what doesn’t, and what the future holds. Clin Genitourin Cancer. 2021;19(2):103–16. https://doi.org/10.1016/j. clgc.2020.11.005
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026
18. Bigot C, Boudier P, Ladoire S, Barthélémy P. Advanced nccRCC: What therapeutic options in 2022? Bull Cancer. 2022;109(2s):2s39–46. https://doi.org/10.1016/S0007-4551(22) 00237-5
19. de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive analysis of survival outcomes in non-clear cell renal cell carcinoma patients treated in clinical trials. Clin Genitourin Cancer. 2017;15(6):652–60.e1. https://doi. org/10.1016/j.clgc.2017.03.004
20. Gupta R, Ornstein MC, Li H, Allman KD, Wood LS, Gilligan T, et al. Clinical activity of ipilimumab plus nivolumab in patients with metastatic non-clear cell renal cell carcinoma. Clin Genitourin Cancer. 2020;18(6):429–35. https://doi.org/10.1016/j. clgc.2019.11.012
21. Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer. 2022;10(2):e003844. https://doi. org/10.1136/jitc-2021-003844
22. Albiges L, Gumey HP, Atduev V., Suraez C, Climent Duran  MA, Pook D, et al. 14480 Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). Ann Oncol. 2022;33(suppl_7):S660–80. https://doi.org/10.1016/j. annonc.2022.07.1551
23. Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, et al. Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol. 2022;40(21):2333–41. https://doi.org/10.1200/JCO.21.01944
24. McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz  P, Matveev VB, et al. Open-label, single-arm, phase ii study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021;39(9):1029–39.
https://doi.org/10.1200/ JCO.20.02365https://doi.org/10.1200/JCO.20.02363
25. Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, et  al. PD-L1 expression in non-clear-cell renal cell carcinoma. Ann Oncol. 2014;25(11):2178–84. https://doi.org/10.1093/ annonc/mdu445
26. McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, et al. The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma. Cancer Immunol Res. 2018;6(7):758–65. https://doi.org/10.1158/2326-6066.CIR-17-0475
27. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. https://doi.org/10.1056/NEJMoa1510665
28. Vogelzang NJ, Olsen MR, McFarlane JJ, Arrowsmith E, Bauer  TM, Jain RK, et al. Safety and efficacy of nivolumab in patients with advanced non-clear cell renal cell carci-noma: Results from the phase IIIb/IV checkMate 374 study. Clin Genitourin Cancer. 2020;18(6):461–8.e3.
https://doi. org/10.1016/j.clgc.2020.05.006
29. Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018;6(1):9. https://doi.org/10.1186/s40425-018-0319-9